Can a new drug combo shrink advanced colorectal tumors?
NCT ID NCT07750041
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial is testing whether an investigational drug called SYS6090, when combined with standard treatments like bevacizumab and chemotherapy, can safely and effectively treat advanced colorectal cancer that cannot be removed by surgery. The study includes adults with a specific type of colorectal cancer (pMMR/MSS) who have already tried standard therapies. Researchers will measure how well the combination works, including tumor shrinkage and how long patients live without the disease progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6090 (an investigational drug) combined with bevacizumab and/or chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial, so the safety and effectiveness of SYS6090 are not yet established. The combination may cause side effects or may not improve outcomes compared to existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE ADVANCED OR METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fujian, Fuzhou, 350014, China